Related Experiment Video
Updated: Oct 27, 2026

Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Tomato- and olive-derived proteins, hydrolysates and peptides in anticancer research: molecular findings and research
Neriman Ezgi Cifte1, Gokhan Gorgisen2, Mecit Halil Oztop1,3
1Department of Food Engineering, Middle East Technical University, Ankara, Türkiye. mecit@metu.edu.tr.
Abstract:
Tomato and olive processing streams contain recoverable proteins, hydrolysates and peptides that have received far less attention than their carotenoids, phenolics and lipids. This review evaluates anticancer-related findings for these materials while separating direct anticancer-related experimental evidence, cancer-relevant mechanistic observations without a direct phenotype, general functional bioactivities and computational predictions. Molecular definition is considered separately from biological evidence. Tomato research includes a partially purified chitin-binding lectin preparation with tumor-related activity and cystine-knot miniproteins with antiangiogenic effects. Olive research includes antiproliferative seed hydrolysates and LLPSY, an isolated peptide tested in human cancer cells. The evidence is strongest in different areas: tomato includes defined antiangiogenic miniproteins tested through endothelial and zebrafish models, whereas olive includes a sequence-resolved peptide tested across several human cancer-cell endpoints. These differences reflect non-matched research designs and do not establish greater anticancer potential for either crop. Nevertheless, direct anticancer-related evidence remains limited and heterogeneous, and its interpretation is constrained by incomplete molecular definition of some active preparations, limited candidate-specific digestion and absorption data, and uncertainty regarding the physiological relevance of many in vitro exposure levels. Most other studies address protein recovery, peptide production, antioxidant or metabolic functions, or in silico prediction; these findings support candidate production or characterization but are not treated as anticancer evidence. Across both crops, the main gap is the incomplete connection between molecular identity, direct target validation, gastrointestinal fate and physiologically plausible in vivo exposure. Future work should strengthen reproducible production, identify the active components of complex preparations, test defined candidates mechanistically and connect biological activity with digestion, exposure and safety.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
PI3K/mTOR/AKT Signaling Pathway
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The Proteasome
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Proteomics
Proteomics is the study of proteomes' function. It involves the large-scale systematic study of the proteome to denote the protein complement expressed by a genome. Scientist Mark Wilkins coined the term proteomics...
